August 18, 2020
In partnership with the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), E-PAGA launched the newest Continuing Education (CE) course, The FDA Bad AdProgram and Prescription Drug Promotion, on July 13, 2020. This highly interactive, Section 508-compliant CE course educates healthcare professionals about the FDA Bad Ad program and the role that FDA’s Office of Prescription Drug Promotion (OPDP) plays in regulating prescription drug promotion and advertising.
Course Highlights:
- Video scenarios featuring related knowledge checks and video debriefings from CDER OPDP personnel
- Comprehensive resources for CDER OPDP, FDA Compliance, and the Bad Ad programs
- Responsive framework optimized for mobile learning
This course is supported by these additional services:
- Dedicated site hosting
- Google Analytics
- Continuing Education Credit
Access the course via the CDERLearn website.
https://fdaopdpbadad.e-paga.com
